A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 34,660 shares of ARCT stock, worth $827,680. This represents 0.04% of its overall portfolio holdings.

Number of Shares
34,660
Previous 31,930 8.55%
Holding current value
$827,680
Previous $1.08 Million 21.8%
% of portfolio
0.04%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$24.35 - $44.39 $66,475 - $121,184
2,730 Added 8.55%
34,660 $843,000
Q1 2024

Apr 17, 2024

BUY
$31.23 - $42.99 $24,296 - $33,446
778 Added 2.5%
31,930 $1.08 Million
Q4 2023

Jan 10, 2024

SELL
$17.71 - $32.97 $415,228 - $773,014
-23,446 Reduced 42.94%
31,152 $982,000
Q3 2023

Oct 27, 2023

BUY
$25.44 - $37.35 $219,470 - $322,218
8,627 Added 18.77%
54,598 $1.39 Million
Q2 2023

Aug 09, 2023

SELL
$23.94 - $32.36 $467,907 - $632,476
-19,545 Reduced 29.83%
45,971 $1.32 Million
Q1 2023

Apr 20, 2023

SELL
$14.72 - $23.97 $28,247 - $45,998
-1,919 Reduced 2.85%
65,516 $1.57 Million
Q4 2022

Jan 12, 2023

BUY
$14.14 - $23.06 $99,998 - $163,080
7,072 Added 11.72%
67,435 $1.14 Million
Q3 2022

Nov 14, 2022

SELL
$13.05 - $22.13 $18,243 - $30,937
-1,398 Reduced 2.26%
60,363 $895,000
Q2 2022

Jul 19, 2022

BUY
$12.26 - $31.17 $29,129 - $74,059
2,376 Added 4.0%
61,761 $972,000
Q1 2022

Apr 26, 2022

BUY
$17.64 - $39.57 $197,832 - $443,777
11,215 Added 23.28%
59,385 $1.6 Million
Q4 2021

Feb 14, 2022

BUY
$34.2 - $47.56 $620,969 - $863,546
18,157 Added 60.5%
48,170 $1.78 Million
Q3 2021

Nov 12, 2021

BUY
$27.88 - $58.25 $286,494 - $598,577
10,276 Added 52.06%
30,013 $1.43 Million
Q2 2021

Aug 13, 2021

BUY
$25.79 - $42.11 $509,017 - $831,125
19,737 New
19,737 $668,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $635M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Hennion & Walsh Asset Management, Inc. Portfolio

Follow Hennion & Walsh Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.